Molecular modelling of trimethoprim complexes of human wild-type and mutant dihydrofolate reductases: Identification of two subsets of binding residues in the antifolate binding site

Biopharmaceutics and Drug Disposition

Volumn 20, Issue 7, 1999, Pages 335-340

  Pan, Ran ^a   Bowen, Donnell ^a   Southerland, William M ^a  

^a HOWARD UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Antifolate resistance; Binding energies; Dihydrofolate reductase; Trimethoprim

Indexed keywords

DIHYDROFOLATE REDUCTASE; FOLIC ACID ANTAGONIST; METHOTREXATE; TRIMETHOPRIM;

ARTICLE; BINDING KINETICS; DRUG BINDING SITE; DRUG PROTEIN BINDING; ENZYME STRUCTURE; MOLECULAR INTERACTION; MOLECULAR MODEL; MOLECULAR STABILITY; STRUCTURE ANALYSIS;

BINDING SITES; CRYSTALLOGRAPHY, X-RAY; FOLIC ACID ANTAGONISTS; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, MOLECULAR; MUTATION; TETRAHYDROFOLATE DEHYDROGENASE; TRIMETHOPRIM;

EID: 0033495368     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-081X(199910)20:7<335::AID-BDD193>3.0.CO;2-A     Document Type: Article

References (38)

1. Kamen B. Folate and antifolate pharmacology. Semin Oncol 1997; 24(Suppl. 18): 30-39.
2. Crown J. Evolution in the treatment of advanced breast cancer. Semin Oncol 1998; 25(Suppl. 12): 12-17.
3. Freeman AI, Wang JJ, Sinks LF. High dose methotrexate in acute lymphocytic leukemia. Cancer Treat Rep 1997; 61: 727-731.
4. Massenkeil G, Spath-Schwalbe E, Flath B, Gottshalk S, Arnold R. Transient tetraparesis after intrathecal and high dose methotrexate. Ann Hematol 1998; 77: 239-242.
5. Khouri IF, Romaguera J, Kantarjian H, Palmer JL, Pugh WC, Korbling M, Hagemeister F, Samuels B, Rodriguez A, Giralt S, Younes A, Przepiorka D, Claxton D, Cabanillas F, Champlin R. Hyper CVAD and high dose methotrexate cytarabine followed by stem cell transplantation: an active regimen for aggressive mantle cell lymphoma. J Clin Oncol 1998; 16: 3803-3809.
6. Seidel H, Nygaard R, Haave I, Moe PJ. Magnetic resonance imaging and neurological evaluation after treatment with high-dose methotrexate for acute lymphocytic leukemia in young children. Acta Paediatr 1996; 85: 450-453.
7. Stoller RG, Hande KR, Jacobs SA, Rosenberg SA, Chabner BA. Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. New Engl J Med 1977; 297: 630-634.
8. Gleckman R, Blagg N, Joubert DW. Trimethoprim: mechanisms of action, antimicrobial activity, bacterial resistance, pharmacokinetics, adverse reactions, and therapeutic indications. Pharmacotherapy 1981; 1: 14-20.
9. Matthews DA, Bolin JT, Burridge JM, Filman DJ, Volz KW, Kraut J. Dihydrofolate reductase: the stereochemistry of inhibitor selectivity. J Biol Chem 1985; 260: 392-399.
10. Thomson CJ. Trimethoprim and brodimoprim resistance of gram-positive and gram-negative bacteria. J Chemother 1993; 5: 458-464.
11. Lane HC, Laughton BE, Fallon J, Kovacs JA, Davey RT, Jr Polis MA, Masur H. Recent advances in the management of AIDS-related opportunistic infections. Ann Intern Med 1994; 120: 945-955.
12. Gallant JE, Moore RD, Chaisson RE. Prophylaxis for opportunistic infections in patients with HIV infections. Ann Intern Med 1994; 120: 932-944.
13. Wormser GP, Keusch GT, Heel RC. Co-trimoxazole (trimethoprim-sulfamethoxazole) an updated review of its antibacterial activity and clinical efficacy. Drugs 1982; 24: 459-515.
14. Palmer KJ, Holliday SM, Brogder RN. Mefloquine: a review of its antimalarial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1993; 45: 430-475.
15. Ferone R, Burchall JJ, Hitching GH. Plasmodium berghei dihydrofolate reductase: isolation, properties, and inhibition by antifolates. Mol Pharmacol 1969; 5: 49-59.
16. van Es, HHG, Skamere E, Schurr E. Chemotherapy of malaria: a battle against all odds. Clin Invest Med 1993; 16: 285-293.
17. Chio LC, Queener SF. Indentification of highly potent and selective inhibitors of Toxoplasma gondii dihydrofolate reductase. Antimicrob Agents Chemother 1993; 37: 1914-1923.
18. McKie JH, Douglas KT, Chan C, Roser SA, Yates R, Read M, Hyde JE, Dascombe MJ, Yuthavong Y, Sirawaraporn W. Rational drug design approach for overcoming drug resistance: application to pyramethamine resistance in malaria. J Med Chem 1998; 41: 1367-1370.
19. Melera P, Davide JP, Hession CA, Scotto KW. Phenotypic expression in Escherichia coli and nucleotide sequence of two chinese hamster lung cell cDNA encoding dihydrofolate reductases. Mol Cell Biol 1984; 4: 38-48.
20. Melera PW, Hession CA, Davide JP, Scotto KW, Biedler JL, Meyers MB, Shanske S. Antifolate-resistant chinese hamster cells: mRNA directed overproduction of multiple dihydrofolate reductases from a series of independently derived sublines containing amplified dihydrofolate reductase genes. J Biol Chem 1982; 257: 12939-12949.
21. Haber DA, Beverly SM, Kiely ML, Schimke RT. Properties of an altered dihydrofolate reductase encoded by amplified genes in cultured mouse fibrolasts. J Biol Chem 1981; 256: 9501-9510.
22. Srimatkandada S, Schweitzer BI, Moroson BA, Dube S, Bertino JR. Amplification of a polymorphic dihydrofolate reductase gene expresing an enzyme with decreased binding to methotrexate in a human colon carcinoma cell line HCT-8R4, resistant to this drug. J Biol Chem 1989; 264: 3524-3528.
23. Miyachi H, Takemura Y, Kobayashi H, Ando Y. Expression of variant dihydrofolate reductases with decreased binding affinity to antifolates in MOLT-3 human leukemia cell lines resistant to trimetrexate. Cancer Lett 1995; 88: 93-99.
24. Simonsen CC, Levinson AD. Isolation and expression of an altered mouse dihydrofolate reductase cDNA. Proc Natl Acad Sci USA 1983; 80: 2495-2499.
25. McIvor RS, Simonson CC. Isolation and characterizaton of a variant dihydrofolate reductase cDNA from methotrexate-resistant murine L517Y cells. Nuc Acids Res 1990; 18: 7025-7032.
26. Grange T, Kunst F, Thillet J, Ribadeau-Dumas B, Mousseron S, Hung A, Picter R. Expression of mouse dihydrofolate reductase cDNA in B. subtilis: a system to select mutant cDNAs coding for methotrexate resistant enzymes. Nuc Acids Res 1984; 12: 3585-3601.
27. Dicker AP, Waltham MC, volkenandt M, Schweitzer BI, Otter GM, Schmid FA, Sirotnak FM, Bertino JR. Methotrexate resistance in an in vivo mouse tumor due to a non-active-site dihydrofolate reductase mutation. Proc Natl Acad Sci USA 1993; 90: 11797-11801.
28. Schweitzer BI, Srimatkandada S, Gristman H, Seridan R, Venkataraghavan R, Bertino JR. Probing the role of two hydrophobic active site residues in the human dihydrofolate reductase by site-directed mutagenesis. J Biol Chem 1989; 264: 20786-20775.
29. Blakley RL, Sorrentino BP. In vitro mutations in dihydrofolate reductase that confer resistance to methotrexate: potential for clinical application. Hum Mutat 1998; 11: 259-263.
30. Morris JA, McIvor RS. Saturation mutagenesis at dihydrofolate reductase codons 22 and 31: a variety of amino acid substitutions conferring methotrexate resistance. Biochem Pharmacol 1994; 47: 1207-1220.
31. Chundura SK, Cody V, Luft JR, Pangborn W, Appleman JR, Blakely RL. Methotrexate-resistant variants of human dihydrofolate reductases: effects of Phe32 substitutions. J Biol Chem 1994; 269: 9547-9555.
32. Cody V, Luft JR, Ciszak E, Kalman TI, Freishein JH. Crystal structure determination at 2.3 Å of recombinant human dihy-drofolate reductase ternary complex with NADPH and methotrexate-gamma-tetrazole. Anti-Cancer Drug Design 1992; 7: 483-491.
33. Lewis WS, Cody V, Galitsky N, Luft JR, Pangborn W, Chunduru SK, Spencer HT, Appleman JR, Blakeley RL. Methotrexate-resistant variants of human dihydrofolate reductase with substitutions of leucine 22: kinetics, crystallography, and potential as selectable markers. J Biol Chem 1995; 270: 5057-5064.
34. Brooks BR, Bruccoleri RE, Olafson BD, States DJ, Swaminathan S, Karplus M. CHARMM: a program for macromolecular energy, minimization, and dynamics calculations. J Comput Chem 1983; 4: 187-217.
35. Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, Klein MC. Comparison of simple potential functions for simulating water. J Chem Phys 1983; 79: 926-935.
36. Nakano T, Spencer HT, Appleman JR, Blakeley RL. Critical role of phenylalanine 34 of human dihydrofolate reductase in substrate and inhibitor binding and in catalysis. Biochemistry 1994; 33: 9945-9952.
37. Thillet J, Absil J, Stone SR. Site-directed mutagenesis of mouse dihydrofolate reductase: mutants with increased resistance to methotrexate and trimethoprim. J Biol Chem 1988; 263: 12500-12508.
38. Searle MS, Forster MJ, Birdsall B, Roberts GL, Feeney J, Cheung HT, Kompis I, Geddes AJ. Dynamics of trimethoprim bound to dihydrofolate reductase. Proc Natl Acad Sci USA 1988; 85: 3787-3791.